Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | (469.1%) | (148.1%) | (55.5%) | (100.7%) | (180.3%) | (96.1%) | (94.3%) | 5.6% | (4.6%) | (53.1%) | (60.6%) | (53.7%) | (6.9%) | 5.4% | 64.4% | 22.4% | 36.7% | 24.9% | 27.7% | 23.0% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is (3.2%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Vertex Pharmaceuticals Incorporated have been 20.5% over the past three years, and 24.5% over the past five years.
As of today, Vertex Pharmaceuticals Incorporated's Return on Equity (ROE) is (3.2%), which is higher than industry median of (51.8%). It indicates that Vertex Pharmaceuticals Incorporated's Return on Equity (ROE) is Good.